NB2222

**NB2222** is an ophthalmic formulation of a proprietary cannabidiol (CBD) analogue, specifically CBD-valine-hemisuccinate (CBDVHS), developed by Nemus Bioscience (later Emerald Bioscience, now Skye Bioscience) in collaboration with the University of Mississippi. Designed as an eye drop emulsion, it exhibits superior ocular penetration across multiple eye chambers, including the anterior compartment, vitreous humor, posterior segment, and optic nerve, enabling potential neuroprotection of retinal ganglion cells. Preclinical studies demonstrate its ability to reduce inflammation and fibrosis biomarkers, positioning it for treating anterior and posterior eye diseases without psychoactive effects associated with THC.[1][2][4][5]